Hemogenyx Pharmaceuticals (LON:HEMO) Posts Quarterly Earnings Results

Hemogenyx Pharmaceuticals (LON:HEMO) announced its earnings results on Thursday. The company reported GBX (170.60) EPS for the quarter, Digital Look Earnings reports.

Hemogenyx Pharmaceuticals Stock Performance

LON:HEMO opened at GBX 672 on Friday. The company has a quick ratio of 6.72, a current ratio of 0.43 and a debt-to-equity ratio of -440.54. The firm’s fifty day simple moving average is GBX 971.75 and its 200 day simple moving average is GBX 833.40. The stock has a market cap of £43.18 million, a P/E ratio of -2.91 and a beta of 1.54. Hemogenyx Pharmaceuticals has a twelve month low of GBX 124 and a twelve month high of GBX 1,800.

Hemogenyx Pharmaceuticals Company Profile

Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood diseases. It is involved in developing products for bone marrow/hematopoietic stem cell (BM/HSC) transplant market, including CDX bi-specific antibody targeting relapsed/refractory acute myeloid leukaemia (R/R AML); HEMO-CAR-T therapy, a chimeric antigen receptor T-cells to identify and destroy human AML-derived cells in vitro and in vivo; and Human Postnatal Hematopoietic Endothelial Cells, a stem cell therapy product for BM/HSC transplants.